All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
China NMPA issue breakthrough therapy designation to APL-106 for relapsed/refractory AML
By Claire Baker
Bookmark this article
On January 7, 2021, the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) granted the E-selectin inhibitor APL-106 breakthrough therapy designation for the treatment of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).
The agent received investigational new drug approval in September 2020, which provided grounds for a future phase III bridging study of APL-106 in combination with chemotherapy for the treatment of R/R AML.1
APL-106
APL-106 is a first-in-class, investigational, targeted inhibitor of the E-selectin adhesion molecule.1 E-selectin is expressed in the bone marrow endothelium and is essential for physiological hematopoietic turnover. Upon interaction with AML cells, however, E-selectin can promote survival and regeneration, and is now a recognized contributor to AML chemoresistance.2
This newly introduced designation is designed to hasten the development and health authority review of APL-106 in R/R AML. Further research will demonstrate whether this new drug provides an advantage over existing treatment options.
- APL-106 (uproleselan) granted breakthrough therapy designation in China for the treatment of acute myeloid leukemia. https://www.globenewswire.com/news-release/2021/01/07/2154803/0/en/APL-106-uproleselan-Granted-Breakthrough-Therapy-Designation-in-China-for-the-Treatment-of-Acute-Myeloid-Leukemia.html. Published Jan 7, 2021. Accessed Jan 7, 2021.
- Barbier V, Erbani J, Fiveash C, et al. Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. Nat Commun. 2020;11:2042. DOI: https://doi.org/10.1038/s41467-020-15817-5
More about...
Your opinion matters
1 vote - 3 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox